Business
PROCEPT BioRobotics Corp. Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue
REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing
About this update from Procept Biorobotics Corporation
[{"type":"text","content":"REDWOOD CITY, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2021. Preliminary, Unaudited Revenue Highlights: Revenue for the fourth quarter of 2021 is expected to be in the range of $9.8 million to $10.1 million, compared to $3.2 million in the prior year period. Total U.S. revenue of $8.4 million to $8.7 million for the fourth quarter of 2021U.S. system sales and rental revenue of approximately $5.0 million and U.S. handpieces and other consumables revenue of approximately $3.4 million for the fourth quarter of 2021Total International revenue of approximately $1.4 million for the fourth quarter of 2021 Fiscal year 2021 revenue is expected to be in the range of $34.1 million to $34.4 million, compared to $7.7 million in fiscal year 2020. “We are very proud to announce that we have exceeded our revenue expectations in the fourth quarter and fiscal year,” said Reza Zadno, Chief Executive Officer of PROCEPT. “The significant growth is being driven by the successful execution of our strategy to deliver on both new system sales and increased procedure adoption for Aquablation therapy. Additionally, our commercial team expansion and physician adoption have been key in our ability to overcome the disruption COVID-19 has had on elective procedures. We believe the numerous benefits of our automated robotic procedure have the ability to change the surgical standard of care in BPH.” The Company plans to release its fourth quarter and full year 2021 financial results in early March 2022. The preliminary results are unaudited and remain subject to adjustment. About PROCEPT BioRobotics CorporationPROCEPT is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT designed Aquablation the...